The frequency of P16INK4A promoter methylation ranged from 17% to 80% (median 44%) in the lung cancer tissue and 0 to 80% (median 15%) in the autologous controls, which shows a great variety of methylation rate between studies. Here, CDKN2A is linked to lung carcinoma.